🏅 FDA Orphan Designation

Isturisa

osilodrostat

Manufacturer: Recordati Rare Diseases, Inc

Indicated for:

Cushing diseaseOrphanLeigh syndrome with nephrotic syndrome

FDA-Approved Indications (2)

ISTURISA is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushingï¿½s disease for whom pituitary surgery is not an option or has not been curative.

Leigh syndrome with nephrotic syndrome

ISTURISA is indicated for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative

Population: adults

Indications & Usage

1 INDICATIONS AND USAGE ISTURISA is indicated for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative. ISTURISA is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative ( 1 )

💙 Support Programs

View all →

Isturisa

Recordati Rare Diseases

Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.